Work

Acalabrutinib vs zanubrutinib as first-line therapy in CLL: A propensity score–matched study

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-6333

Authors: Angimar Uriepero, Jose Milano, Valeria Ziegler, Akshay Ratnani, Gabor Varadi

Institutions: Thomas Jefferson University, Jefferson Einstein Philadelphia Hospital, Universidad Central de Venezuela

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417021905

Cites:

Cited by:

Related to: